Figure. OTVR meter, OTR app, and CLOUD data collection. CLOUD; OTR, OneTouch Reveal; OTVR, OneTouch Verio Reflect.
Using data from the Lifescan server, researchers sought to provide real-world evidence, that their products—the OneTouch Verio Reflect (OTVR) meter which provides ColorSure Dynamic Range Indicator (DCRI) and Blood Sugar Mentor (BSM) features that are complemented by the OneTouch Reveal (OTR) mobile app—support improved blood glucose control.
Anonymized glucose and app analytics were extracted from the LifeScan server for 4154 people with type 1 diabetes (PwT1D) and 13,623 people with type 2 diabetes (PwT2D). Data from their first 14 days using the products were compared with the 14 days before the 90-day time point using paired within-subject differences.
The researchers reported the percentage glucose readings in range (RIR) 70–180mg/dL improved by +8.1% (from 58% to 66.1%) in PwT1D and by +11.2% (from 72.4% to 83.6%) in PwT2D. Hyperglycemic readings (>180mg/dL) reduced by -8.5% (from 37.1% to 28.6%) in PwT1D and by -11.3% (from 26.4% to 15.1%) in PwT2D. Mean glucose reduced on average by -14.5 mg/dL (from 174.8 to 160.2 mg/dL) in PwT1D and -18.2mg/dL (from 157.8 to 139.6mg/dL) in PwT2D. Glycemic improvement was strongly associated with OTR app engagement. Two to three sessions or 11 to 20 min/week in the app improved readings in range in PwT1D by +7.0% or +8.4%, respectively. Similar engagement trends for glycemic improvement were observed in PwT2D. Proportions of subjects achieving a 5% or 10% improvement in RIR were 46.9%/36.6% for PwT1D and 48.7%/37.7% for PwT2D.
The researchers concluded that real-world data from over 17,000 people with diabetes (PWDs) demonstrated significantly improved readings in range and reduced the burden of hyperglycemia in PWDs using the OTVR meter and OTR app.
Source: Grady M, Cameron H, Bhatiker A, Holt E, Schnell O. Real-World Evidence of Improved Glycemic Control in People with Diabetes Using a Bluetooth-Connected Blood Glucose Meter with a Mobile Diabetes Management App. Diabetes Technol Ther. 2022 Oct;24(10):770-778. doi: 10.1089/dia.2022.0134.
